Supplementary Table 4. characteristics and association between OC use and endometrial cancer incidence a Details OR b 95% CI Covariates Region Case-control Parslov, 2000 (1) Danish women aged 25 49 yr Cases: 237 endometrial cancer, hospital Controls: 538, Central Person Register NR NR NA Denmark Good 2 Maxwell, 2006 (2) Recruitment period: 1987 1994 Women aged 20 54 yr in Cancer and Steroid Hormone Cases: 434 endometrial cancer, SEER registry Controls: 2557, population NA U.S. Good 1 High progestin/high estrogen High progestin/low estrogen Low progestin/high estrogen Low progestin/low estrogen 0.21 0.00 0.39 0.40 0.10 to 0.43 0.00 to 5.59 0.25 to 0.60 0.21 to 0.76 Tao, 2006 (3) Recruitment period: 1980 1982 Women aged 30 69 yr in Shanghai Endometrial Cancer Cases: 1204 endometrial cancer, registry Controls: 1212 no history of hysterectomy, resident registry Recruitment period: 1997 2003 0.75 0.60 to 0.93 menopausal status, BMI, family history, age at menarche, education, yr of menstruation, family history of breast, endometrial, and colon cancers, age at last live birth, physical activity, exogenous hormone use China Good 1 1
a Details OR b 95% CI Covariates Region Urban, 2012 (4) Black South African women aged 18 79 yr Cases: 17, hospital Controls: 156, hospital Cohort Vessey, 2006 (5) Recruitment period: 1995 2006 Women aged 25 39 yr in Oxford Family Planning Association Contraceptive Exposed: 301,000 person-years Unexposed: 187,000 person-years 1.01 0.55 to 1.85 0.3 0.2 to 0.6 smoking, year of diagnosis, education, alcohol consumption, sexual partners, urban/rural residence, province of birth BMI, smoking, social class, height, age at first term pregnancy, age at first marriage South Africa Good 1 UK Good 1 Hannaford, 2007 (6) Recruitment period: 1968 1974 Royal College of General Practitioner s Oral Contraception Exposed: 744,000 person-years Unexposed: 339,000 person-years 0.58 0.42 to 0.79 smoking, social status UK Fair 1 Setiawan, 2007 (7) Mean age at study entry: 29 (SD 6.6) Recruitment period: 1968 NR Women aged 45 75 yr in Multiethnic Cohort Hawaii and Los Angeles 46,933 (total population of exposed and unexposed, postmenopausal women) NR NR NA U.S. Good 2 Rosenblatt, 2009 (8) Recruitment period: 1993 1996 Textile workers in Shanghai aged 30 64 yr Exposed: 352,695 person-years Unexposed: 2,057,377 person-years 0.68 0.45 to 1.04 tubal ligation China Poor 1 Recruitment period: 1989 1991 2
a Details OR b 95% CI Covariates Region Dossus, 2010 (9) European Prospective Investigation into Cancer and Nutrition Exposed: 1017 Unexposed: 301,601 0.65 0.56 to 0.75 BMI, smoking, physical activity, alcohol, diabetes, education 10 European countries Fair 1 1017 Cases, 301601 Cases Mean age of cases at entry: 56.2 Recruitment period: 1992 NR BMI, body mass index; CI, confidence interval; NA, not applicable; NR, not reported; OC, oral contraceptive; OR, odds ratio; UK, United Kingdom; U.S., United States; yr, year/years. a identifies the primary abstracted article. For details about the relationships between companion studies and articles, refer to Tables C-1 and C-2 in Appendix C. b Odds ratio for meta-analysis of ever versus never OC use. c analysis code: 1 = Included in this meta-analysis; 2 = Excluded due to ever versus never OR not reported. 3
References for Supplementary Table 4 1. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 2000;182:23-9. 2. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40. 3. Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT, Ruan ZX, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer 2006;119:2142-7. 4. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med 2012;9:e1001182. 5. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9. 6. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651. 7. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007;165:262-70. 4
8. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control 2009;20:27-34. 9. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;127:442-51. 5